A Trial to Evaluate the Precision and Accuracy of the NBM-200 Series When Used in a Continuous Prospective Mode

Anemia Clinical Trial

Official title:

A Trial to Evaluate the Precision and Accuracy of the NBM-200 Series When Used in a Continuous Prospective Mode

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01917487
• Other study ID #: QD04.5.1-25
• Status: Active, not recruiting
• Phase: N/A
• First received: August 1, 2013
• Last updated: September 9, 2013
• Start date: November 2011
• Est. completion date: November 2013

Study information

• Verified date: September 2013
• Source: OrSense, Ltd.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Israel: Ministry of Health
• Study type: Observational

Clinical Trial Summary

The purpose of the study is to define the precision, accuracy and variability of the NBM-200 system in non invasive blood Hemoglobin (Hb) measurements relative to the laboratory blood analyzer by comparing two consecutive Hb values obtained by the NBM system to venous values.

Description:

Each subject will be placed in a comfortable position in a temperature regulated room. Participants will have two consecutive non invasive (NBM) measurements taken which involves inserting the thumb into a ring shaped sensor. After each non invasive measurement the sensor will be removed. Each measurement takes approximately 85 seconds and involves the finger cuff inflating (to over systolic pressure) and deflating several times in quick successions in order to measure and calculate the Hb values. The two non invasive measurements will be performed using the same finger. After the NBM system testing is complete and recorded, the subject will have a venous (venipuncture) blood sample collected in order to provide two blood tests performed on two different models of routine automated complete blood count or Hb blood analyzers.

Addendum:

Reproducibility Procedure (optional) Each subject will be measured by each one of the three operators, three NBM system units, 3 times consecutively (without removal) on his right thumb and right index finger. The order of each measurement sequence will be randomized (thumb/index). There will be an intermission of 3 to 5 minutes between the 3 measurement sets taken on each participant. In case of a longer intermission, the subject will be measured again and the previous results will be excluded.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 150
• Est. completion date: November 2013
• Est. primary completion date: October 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 95 Years

Eligibility

Inclusion Criteria:

• Aged 18 years and over

• Healthy volunteers

• Anemia patients

Exclusion Criteria:

• Participants under the age of 18 years

• Patients with significant deformity, degenerative changes or oedema of the thumb or index fingers

• Patients with localized infection, ulceration or skin breaks involving the fingers

• Patients with vascular disease or Raynaud's phenomenon affecting the fingers

• Participants who are unable to give informed written consent

• Pregnancy

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Anemia

Locations

Country	Name	City	State
Israel	The Chaim Sheba Medical Center at Tel Hashomer	Ramat Gan

Sponsors (1)

Lead Sponsor	Collaborator
OrSense, Ltd.

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Compare the Hb values from the Noninvasive Blood Monitor(NBM200) series against the Hb from the lab blood analyser on healthy volunteers and oncology patients		1 day	No